Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors

P Nambi, N Elshourbagy, HL Wu, M Pullen, EH Ohlstein, DP Brooks, MA Lago, JD Elliott, JG Gleason and RR Ruffolo

Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania.

The effect of a series of endothelin (ET) receptor antagonists, including the novel nonpeptide receptor antagonist, SB 209670, on [125I]ET-1 binding to human ET receptors (ETA and ETB) cloned and stably expressed in Chinese hamster ovary cells was studied. SB 209670 was found to compete for [125I]ET-1 binding with apparent Ki values of 0.43 +/- 0.09 and 14.7 +/- 3.0 nM for ETA and ETB receptors, respectively. This inhibition was competitive because addition of SB 209670 in saturation binding experiments resulted in decreased affinity, with no change in maximum binding. In addition, SB 209670 inhibited ET-1-mediated accumulation of inositol phosphates and intracellular calcium release in a concentration-dependent manner. The racemic mixtures, (+/-)-SB 209670 and (-)-SB 209670, were approximately 1.5 and at least 200-fold less potent than SB 209670. The binding affinity of (+/-)-SB 209670 therefore resides in (+)-antipode. The peptide antagonists, BQ123 (ETA-selective) and RES 701 (ETB-selective), were 40- and 6-fold less potent than SB 209670 in inhibition of [125I] ET-1 binding to ETA and ETB receptors, respectively. The nonselective peptide antagonist, PD 142893, was 75- and 10-fold less potent than SB 209670, whereas the nonpeptide antagonist, bosentan, was approximately 80- and approximately 30-fold less potent than SB 209670 in inhibition of [125I]ET-1 binding to ETA and ETB receptors, respectively. Thus, the present studies indicate clearly that SB 209670 is the most potent nonpeptide ET receptor antagonist yet described.

Volume 271, Issue 2, pp. 755-761, 11/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. H. Damon NGF-independent survival of postganglionic sympathetic neurons in neuronal-vascular smooth muscle cocultures Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1722 - H1728. [Abstract] [Full Text] [PDF]

				C. Y. Pang, J. Zhang, H. Xu, J. E. Lipa, C. R. Forrest, and P. C. Neligan Role and mechanism of endothelin-B receptors in mediating ET-1-induced vasoconstriction in pig skin Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1998; 275(4): R1066 - R1074. [Abstract] [Full Text] [PDF]

				E. H. Ohlstein, P. Nambi, D. W. P. Hay, M. Gellai, D. P. Brooks, J. Luengo, J.-N. Xiang, and J. D. Elliott Nonpeptide Endothelin Receptor Antagonists. XI. Pharmacological Characterization of SB 234551, a High-Affinity and Selective Nonpeptide ETA Receptor Antagonist J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 650 - 656. [Abstract] [Full Text]

				P. Cernacek, L. Franchi, J. Dupuis, J.-L. Rouleau, and M. Levy Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine Clin. Chem., August 1, 1998; 44(8): 1666 - 1673. [Abstract] [Full Text] [PDF]

				T. E. Rasmussen, M. Jougasaki, T. Supaporn, J. W. Hallett Jr., D. P. Brooks, and J. C. Burnett Jr. Cardiovascular actions of ET-B activation in vivo and modulation by receptor antagonism Am J Physiol Regulatory Integrative Comp Physiol, January 1, 1998; 274(1): R131 - R138. [Abstract] [Full Text] [PDF]

				P. Nambi, M. Pullen, J. Kincaid, P. Nuthulaganti, N. Aiyar, D. P. Brooks, M. Gellai, and C. Kumar Identification and Characterization of a Novel Endothelin Receptor That Binds Both ETA- and ETB-Selective Ligands Mol. Pharmacol., October 1, 1997; 52(4): 582 - 589. [Abstract] [Full Text]

				S. A. Douglas, M. Gellai, M. Ezekiel, G. Z. Feuerstein, J. D. Elliott, and E. H. Ohlstein Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 Hypertension, April 1, 1995; 25(4): 818 - 822. [Abstract] [Full Text]